A double-blind, randomized, multiple-dose and single-dose crossover, 2-part study to evaluate safety, tolerability and pharmacokinetics of injectable WCK 4282 (FEP-TAZ) in healthy male and female subjects.
Latest Information Update: 12 May 2017
At a glance
- Drugs Cefepime/tazobactam (Primary)
- Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections
- Focus Adverse reactions; Pharmacokinetics
- 12 May 2017 New trial record
- 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases